Filtered By:
Therapy: Cancer Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 13617 results found since Jan 2013.

Cancer-Related Search for Meaning Increases Willingness to Participate in Mindfulness-Based Stress Reduction
Conclusion. Our study indicates that patients searching for meaning are receptive to MBSR. Nonwhite patients and those experiencing high levels of anxiety are most likely to endorse a search for meaning. Future research is needed to understand how best to support patients who are searching for meaning and remove barriers to evidence-based programs like MBSR.
Source: Integrative Cancer Therapies - April 13, 2015 Category: Cancer & Oncology Authors: Garland, S. N., Stainken, C., Ahluwalia, K., Vapiwala, N., Mao, J. J. Tags: Articles Source Type: research

Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Abstract Since the approval of the proteasome inhibitor, Velcade(®), by the Food and Drug Administration (FDA) for the treatment of relapsed multiple myeloma, inhibitors of the ubiquitin-proteasome system have been attracting increasing attention as promising drug leads for cancer therapy. While the development of drugs for diseases related to this proteolytic system has mainly been achieved by searching libraries of synthetic small molecules or chemical modifications to drug leads, limited searches have been conducted on natural sources. We have been searching natural sources for inhibitors that target this prot...
Source: Chemical and Pharmaceutical Bulletin - February 3, 2016 Category: Drugs & Pharmacology Authors: Tsukamoto S Tags: Chem Pharm Bull (Tokyo) Source Type: research

Current studies of immunotherapy in head and neck cancer
ConclusionNumerous clinical trials are addressing the suitability and efficacy of immune checkpoint modulators in HNSCC with the predominant targets being the established immune checkpoint receptors PD‐1/PD‐L1 and CTLA‐4. Recently presented results have shown a survival benefit, a favorable safety profile and an extended duration of response in favor of using immune checkpoint modulation in R/M HNSCC.This article is protected by copyright. All rights reserved.
Source: Clinical Otolaryngology - May 2, 2017 Category: ENT & OMF Authors: Volkan Dogan, Thorsten Rieckmann, Adrian M ünscher, Chia‐Jung Busch Tags: Original Article Source Type: research

Abstract IA24: Tolerability and efficacy of antiangiogenic agents and novel combinations - In search of the optimal therapeutic windows
Antiangiogenic agents are associated with toxicities due to "on-target" effects on neoangiogenesis, vascular dynamics and tissue repair as well as "off-target" side effects in the case of small molecular inhibitors. Nevertheless, the therapeutic window has proven to be adequate for conferring important clinical benefits in a number of advanced tumors. As antiangiogenic therapies became widely used in patient care, progresses have been made in the efforts to identify risk factors of serious adverse reactions and establish guidelines for risk mitigation. Still, therapeutic outcomes with individual agents are limited by the c...
Source: Molecular Cancer Therapeutics - December 6, 2015 Category: Cancer & Oncology Authors: Chen, H. X. Tags: Antiangiogenesis: Safety Issues and Endothelial Metabolism: Oral Presentations - Invited Abstracts Source Type: research

Cancers, Vol. 10, Pages 417: Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review
The objective of this study was to conduct a descriptive review of current data on survival outcomes of systemic anti-cancer therapy specific to SS. A systematic literature review was conducted, using a custom search strategy to search EMBASE, Medline and CENTRAL for clinical trials and observational studies reporting overall survival (OS), progression-free survival (PFS) and/or response for cohorts of at least 50 SS patients. We identified 28 studies meeting these criteria, 25 of which were retrospective studies. Only three prospective studies were identified. Survival reports varied widely between studies based on the po...
Source: Cancers - November 1, 2018 Category: Cancer & Oncology Authors: Richard F. Riedel Robin L. Jones Antoine Italiano Chet Bohac Juliette C. Thompson Kerstin Mueller Zaeem Khan Seth M. Pollack Brian A. Van Tine Tags: Review Source Type: research

Active search for oral complications during systemic cancer therapy
Introduction: Oral side effects related to cancer therapies and dental disease are associated with a legion of signs and complaints in the head and neck region. A wide number of oncologic therapy is carried out in the ambulatory care setting. However, there is little information about the oral health and complaints associated with each treatment in these patients. Objectives: To identify the need for oral care through an active search of oral problems during systemic cancer therapy in outpatients.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - August 31, 2020 Category: ENT & OMF Authors: NAARA CRISTINA CARVALHO DOS SANTOS, LEANDRO DORIGAN DE MACEDO, LIANE RAPATONI, TATIANE CARDOSO MOTTA, MATHEUS BARILLARI, ANA RAPHAELA MAIA DEZAN COUTO CURVO, LARA MARIA ALENCAR RAMOS INNOCENTINI Tags: 20190398 Source Type: research

Internet Search Trends Relevant to Interventional Oncology: A Google Trends Study (2004 –2020)
This study pinpoints temporal and geographical trends of public online searches for terms related to the field, as well as IR-related cancer therapies. Google Trends data were analyzed for long-term (2004 –2020) trends in the United States and worldwide. Overall, search interest for IR increased throughout the United States but decreased globally.
Source: Journal of Vascular and Interventional Radiology : JVIR - July 19, 2021 Category: Radiology Authors: Philipp Berning, Majid Maybody, Amy R. Deipolyi, Stephen B. Solomon, Omar Dzaye Tags: Brief Report Source Type: research

Seleno-vs. thioether triazine derivatives in search for new anticancer agents overcoming multidrug resistance in lymphoma
Eur J Med Chem. 2022 Sep 19;243:114761. doi: 10.1016/j.ejmech.2022.114761. Online ahead of print.ABSTRACTLymphomas are still difficult to treat even with modern therapies as, among others, multidrug resistance (MDR) is often counteracting a successful cancer therapy. P-gp/ABC-transporters are well-known for their crucial role in the main tumour MDR mechanism, eliminating drugs and cytotoxic substances from the cancer cell by efflux, and their modulators are promising for innovative therapy, but none has been approved in the pharmaceutical market yet. Herein, we have designed, synthesised and analysed 30 novel seleno- and t...
Source: European Journal of Medicinal Chemistry - September 30, 2022 Category: Chemistry Authors: Wesam Ali Sabrina Garbo Annam ária Kincses M árta Nové Gabriella Spengler Elisabetta Di Bello Ewelina Honkisz-Orzechowska Tadeusz Karcz Ewa Szyma ńska Ewa Żesławska Ma łgorzata Starek Monika D ąbrowska Wojciech Nitek Katarzyna Kucwaj-Brysz Patryk Source Type: research

Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.
CONCLUSION: Bayesian trials have the increased flexibility in trial design needed for personalized medicine, resulting in more cooperation among researchers working to fight against cancer. Some disadvantages of Bayesian trials remain, but new methods and software are available to improve their function and incorporation into cancer clinical research. PMID: 31450957 [PubMed - as supplied by publisher]
Source: Clinical Trials - August 25, 2019 Category: Research Authors: Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ Tags: Clin Trials Source Type: research

Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
CONCLUSIONS: The available evidence on the benefits and harms of CAR T-cell therapy for people with r/r DLBCL is limited, mainly because of the absence of comparative clinical trials. The results we present should be regarded in light of this limitation and conclusions should be drawn very carefully. Due to the uncertainty in the current evidence, a large number of ongoing investigations and a risk of substantial and potentially life-threatening complications requiring supplementary treatment, it is critical to continue evaluating the evidence on this new therapy.PMID:34515338 | DOI:10.1002/14651858.CD013365.pub2
Source: Cochrane Database of Systematic Reviews - September 13, 2021 Category: General Medicine Authors: Moritz Ernst Annika Oeser Burcu Besiroglu Julia Caro-Valenzuela Mohamed Abd El Aziz Ina Monsef Peter Borchmann Lise J Estcourt Nicole Skoetz Marius Goldkuhle Source Type: research

Effectiveness of Melatonin Adjuvant Treatment in Cisplatin to Prevent Depletion of Ovarian Follicles in Mice: Systematic Review
CONCLUSION: Melatonin variation in efficacy varies according to the dose used in mice previously exposed to cisplatin. However, melatonin was able to alter the p-PTEN and p-FOX3a / FOXO3a pathways.PMID:35980799 | DOI:10.1093/biolre/ioac164
Source: Biology of Reproduction - August 18, 2022 Category: Reproduction Medicine Authors: Tairini Damiani Rodrigues Kellen R Lima Maria Laura R Uggioni Sarah Dagostin Ferraz Hemmylly Silveira Cardoso Tamy Colonetti Maria In ês da Rosa Source Type: research